- ￥409 - 4200
- MedChemExpress(MCE)
- 美国
- HY-13820
- 2025年12月05日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
Powder: -20°C, 3 years; 4°C, 2 years.In solvent: -80°C, 6 months; -20°C, 1 month.
- 库存：
货期：1-2天
- 供应商：
MedChemExpress LLC
- CAS号：
1337532-29-2
- 规格：
10 mM * 1 mL/1 mg/5 mg/10 mg/50 mg/100 mg
| 规格： | 10 mM * 1 mL | 产品价格： | ￥770.0 |
|---|---|---|---|
| 规格： | 1 mg | 产品价格： | ￥409.0 |
| 规格： | 5 mg | 产品价格： | ￥700.0 |
| 规格： | 10 mg | 产品价格： | ￥1200.0 |
| 规格： | 50 mg | 产品价格： | ￥2550.0 |
| 规格： | 100 mg | 产品价格： | ￥4200.0 |
MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。
GSK2656157
CAS No. : 1337532-29-2
MCE 国际站：GSK2656157
产品活性：GSK2656157 是选择性，ATP竞争性的 PERK 抑制剂，IC50 值为 0.9 nM。
研究领域：Cell Cycle/DNA Damage | Autophagy | Apoptosis
作用靶点：PERK | Autophagy | Apoptosis
In Vitro: GSK2656157 results in inhibition of PERK activation as well as decreases in the downstream substrates, phospho-eIF2α, ATF4, and CHOP with an IC50?in the range of 10-30 nM in the BxPC3 pancreatic tumor cell line. Cells that are exposed to 1 μM GSK2656157 before UPR induction are able to block this effect on de novo protein synthesis.
GSK2656157 causes the activation of another eIF2α kinase to compensate for the loss of PERK activity in HT1080 cells. GSK2656157 inhibits the growth of the HT1080 cells.
GSK2656157 inhibits LPS-induced IL-1β production, LPS-induced Caspase 1 activation and LPS-induced eIF-2α phosphorylation, but does not inhibit LPS-induced TNF-α production.
In Vivo: GSK2656157 (1.5-150 mg/kg, p.o.) results in dose-dependent inhibition of phospho-PERK Thr980, with more than 80% inhibition at 50 and 150 mg/kg. GSK2656157 (50-150 mg/kg, p.o.) results in dose-dependent inhibition of tumor growth in human tumor xenograft models.
相关产品：Bioactive Compound Library Plus | Apoptosis Compound Library | Cell Cycle/DNA Damage Compound Library | Kinase Inhibitor Library | Anti-Cancer Compound Library | Autophagy Compound Library | Anti-Aging Compound Library | Endoplasmic Reticulum Stress Compound Library | Pyroptosis Compound Library | Targeted Diversity Library | Heterocyclic Compound Library | Highly Selective Inhibitors Library | Highly Selective Activators Library | Cell Death Library | MG-132 | Doxorubicin hydrochloride | Bafilomycin A1 | LY294002 | Tamoxifen | Paclitaxel | Y-27632 | Acetylcysteine | Angiotensin II human | 2-Deoxy-D-glucose | Staurosporine | SB-431542 | Actinomycin D | Deferoxamine mesylate | Bortezomib | 5-Fluorouracil | Trametinib | Sorafenib | Oxaliplatin | Gemcitabine | Temozolomide | Rotenone | Mdivi-1 | Elesclomol | Ruxolitinib | Decitabine | SP600125 | MK-2206 dihydrochloride | Etoposide | Monomethyl auristatin E
热门产品线：重组蛋白 | 化合物库 | 天然产物 | 荧光染料 | PROTAC | 同位素标记物
Trending products：Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Dye Reagents | PROTAC | Isotope-Labeled Compounds
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验真爱满行囊 我最近在体外细胞做的关于gsk3-beta功能问题，发现药物处理以后，gsk-3-beta的总表达量下调，如果是这样的话 1、我是否能够得出gsk-3-beta的活性下调的结论？ 2、是否还有必要做非活性形式的表达量？我的理解是，基础状态下，gsk-3beta维持的是低活性状态，如果总量都下调了，那应该能够得出活性降低的结论了吧？ 3、另外，在这种情况下我是否有必要去做gsk-3-beta的216位点的活性形式的表达
以下是美国冷泉港(CSHL)Hannon领导的研究小组报道的29bp shRNA可以在哺乳动物中起RNAi效应： Paddison PJ, et al. Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev. 2002 Apr 15;16(8):948-58. 免费全文网址：http://www.genesdev.org/cgi/content/full/16
Mesoderm induction and dorso-ventral axial patterning TGF-β receptor (3) ; Xwnt-8 (4) ; Raf-1 (5) ; FGF receptor (6) ; FGF receptor/ activin (7) ; BMP (8) ; N-cadherin (9) ; GSK-3 (10) ; brachyury/pintallavis
技术资料暂无技术资料 索取技术资料
